-
1
-
-
67649131017
-
The Simcyp population-based ADME simulator
-
Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A,. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
-
(2009)
Expert Opin Drug Metab Toxicol
, vol.5
, pp. 211-223
-
-
Jamei, M.1
Marciniak, S.2
Feng, K.3
Barnett, A.4
Tucker, G.5
Rostami-Hodjegan, A.6
-
2
-
-
84862777920
-
The role of physiologically based pharmacokinetic modeling in regulatory review
-
Huang SM, Rowland M,. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012; 91 (3): 542-549.
-
(2012)
Clin Pharmacol Ther
, vol.91
, Issue.3
, pp. 542-549
-
-
Huang, S.M.1
Rowland, M.2
-
3
-
-
67649392513
-
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates
-
Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
-
(2009)
Drug Metab Pharmacokinet
, vol.24
, pp. 53-75
-
-
Jamei, M.1
Dickinson, G.L.2
Rostami-Hodjegan, A.3
-
4
-
-
78951482203
-
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review
-
Zhao P, Zhang L, Grillo JA, et al,. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89: 259-267.
-
Clin Pharmacol Ther
, vol.89
, pp. 259-267
-
-
Zhao, P.1
Zhang, L.2
Grillo, J.A.3
-
5
-
-
0028124656
-
Effect of age and disease on two drug binding proteins: Albumin and alpha-1-acid glycoprotein
-
Woo J, Chan HS, Or KH, Arumanayagam M,. Effect of age and disease on two drug binding proteins: albumin and alpha-1-acid glycoprotein. Clin Biochem 1994; 27: 289-292.
-
(1994)
Clin Biochem
, vol.27
, pp. 289-292
-
-
Woo, J.1
Chan, H.S.2
Or, K.H.3
Arumanayagam, M.4
-
6
-
-
23944497385
-
Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women
-
Engeland A, Tretli S, Austad G, Bjorge T,. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control 2005; 16: 987-996.
-
(2005)
Cancer Causes Control
, vol.16
, pp. 987-996
-
-
Engeland, A.1
Tretli, S.2
Austad, G.3
Bjorge, T.4
-
7
-
-
79958703775
-
Cancer screening in older adults: What to do when we don't know
-
Alibhai SMH, and, Horgan AM,. Cancer screening in older adults: What to do when we don't know. Journal of Geriatric Oncology 2011; 2 (3): 149-160.
-
(2011)
Journal of Geriatric Oncology
, vol.2
, Issue.3
, pp. 149-160
-
-
Alibhai, S.M.H.1
Horgan, A.M.2
-
8
-
-
0023690101
-
Drug binding to human alpha-1-acid glycoprotein in health and disease
-
Kremer JM, Wilting J, Janssen LH,. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1-47.
-
(1988)
Pharmacol Rev
, vol.40
, pp. 1-47
-
-
Kremer, J.M.1
Wilting, J.2
Janssen, L.H.3
-
9
-
-
0025319172
-
The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein
-
Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J,. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990; 29: 201-206.
-
(1990)
Br J Clin Pharmacol
, vol.29
, pp. 201-206
-
-
Veering, B.T.1
Burm, A.G.2
Souverijn, J.H.3
Serree, J.M.4
Spierdijk, J.5
-
10
-
-
0021200499
-
Effect of age and sex on the plasma binding of acidic and basic drugs
-
Verbeeck RK, Cardinal JA, Wallace SM,. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27: 91-97.
-
(1984)
Eur J Clin Pharmacol
, vol.27
, pp. 91-97
-
-
Verbeeck, R.K.1
Cardinal, J.A.2
Wallace, S.M.3
-
11
-
-
0019220256
-
Disease-induced changes in the plasma binding of basic drugs
-
Piafsky KM,. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246-262.
-
(1980)
Clin Pharmacokinet
, vol.5
, pp. 246-262
-
-
Piafsky, K.M.1
-
12
-
-
0034894719
-
Human alpha-1-glycoprotein and its interactions with drugs
-
Israili ZH, Dayton PG,. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33: 161-235.
-
(2001)
Drug Metab Rev
, vol.33
, pp. 161-235
-
-
Israili, Z.H.1
Dayton, P.G.2
-
13
-
-
77249090840
-
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance
-
Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A,. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49: 189-206.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 189-206
-
-
Johnson, T.N.1
Boussery, K.2
Rowland-Yeo, K.3
Tucker, G.T.4
Rostami-Hodjegan, A.5
-
14
-
-
33745130722
-
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
-
Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A,. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006; 36: 473-497.
-
(2006)
Xenobiotica
, vol.36
, pp. 473-497
-
-
Howgate, E.M.1
Rowland Yeo, K.2
Proctor, N.J.3
Tucker, G.T.4
Rostami-Hodjegan, A.5
-
15
-
-
33745181651
-
Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences
-
Inoue S, Howgate EM, Rowland-Yeo K, et al,. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006; 36: 499-513.
-
(2006)
Xenobiotica
, vol.36
, pp. 499-513
-
-
Inoue, S.1
Howgate, E.M.2
Rowland-Yeo, K.3
-
17
-
-
7444242095
-
Bicalutamide: Clinical pharmacokinetics and metabolism
-
Cockshott ID,. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004; 43: 855-878.
-
(2004)
Clin Pharmacokinet
, vol.43
, pp. 855-878
-
-
Cockshott, I.D.1
-
18
-
-
79959584649
-
NCT01110291: Induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer
-
Hilli J, Sailas L, Jyrkkio S, Pyrhonen S, Laine K,. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol 2011; 67: 1353-1362.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 1353-1362
-
-
Hilli, J.1
Sailas, L.2
Jyrkkio, S.3
Pyrhonen, S.4
Laine, K.5
-
19
-
-
76149087823
-
The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects
-
Stroh M, Dishy V, Radziszewski W, et al,. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. Am J Ther 2010; 17: 53-60.
-
(2010)
Am J Ther
, vol.17
, pp. 53-60
-
-
Stroh, M.1
Dishy, V.2
Radziszewski, W.3
-
20
-
-
77955262859
-
An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers
-
Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD,. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clin Ther 2010; 32: 1372-1386.
-
(2010)
Clin Ther
, vol.32
, pp. 1372-1386
-
-
Tomkinson, H.K.1
Kemp, J.V.2
Wollseifen, T.3
Morris, T.4
Oliver, S.D.5
-
21
-
-
77955549620
-
Effect of glycyrrhizin on the activity of CYP3A enzyme in humans
-
Tu JH, He YJ, Chen Y, et al,. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol 2010; 66: 805-810.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, pp. 805-810
-
-
Tu, J.H.1
He, Y.J.2
Chen, Y.3
-
23
-
-
0029988526
-
Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: Role of altered protein binding
-
Aguirre C, Troconiz IF, Valdivieso A, et al,. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Res Commun Mol Pathol Pharmacol 1996; 92: 53-72.
-
(1996)
Res Commun Mol Pathol Pharmacol
, vol.92
, pp. 53-72
-
-
Aguirre, C.1
Troconiz, I.F.2
Valdivieso, A.3
-
24
-
-
3843133122
-
Population pharmacokinetics of APOMINE: A meta-analysis in cancer patients and healthy males
-
Bonate PL, Floret S, Bentzen C,. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol 2004; 58: 142-155.
-
(2004)
Br J Clin Pharmacol
, vol.58
, pp. 142-155
-
-
Bonate, P.L.1
Floret, S.2
Bentzen, C.3
-
25
-
-
65249087328
-
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
Houk BE, Bello CL, Kang D, Amantea M,. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-2506.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
26
-
-
75749146667
-
Population pharmacokinetic model of PI-88, a heparanase inhibitor
-
Hudachek SF, Eckhardt SG, Hicks B, Gustafson DL,. Population pharmacokinetic model of PI-88, a heparanase inhibitor. Cancer Chemother Pharmacol 2010; 65: 743-753.
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 743-753
-
-
Hudachek, S.F.1
Eckhardt, S.G.2
Hicks, B.3
Gustafson, D.L.4
-
27
-
-
33746871799
-
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients
-
Perez-Ruixo JJ, Piotrovskij V, Zhang S, Hayes S, De Porre P, Zannikos P,. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 2006; 62: 81-96.
-
(2006)
Br J Clin Pharmacol
, vol.62
, pp. 81-96
-
-
Perez-Ruixo, J.J.1
Piotrovskij, V.2
Zhang, S.3
Hayes, S.4
De Porre, P.5
Zannikos, P.6
-
28
-
-
0031847284
-
Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients
-
Piotrovsky VK, Huang ML, Van Peer A, Langenaecken C,. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer Chemother Pharmacol 1998; 42: 221-228.
-
(1998)
Cancer Chemother Pharmacol
, vol.42
, pp. 221-228
-
-
Piotrovsky, V.K.1
Huang, M.L.2
Van Peer, A.3
Langenaecken, C.4
-
29
-
-
26944440101
-
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics
-
Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T,. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 2005; 44: 1179-1189.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 1179-1189
-
-
Ishizawa, Y.1
Yasui-Furukori, N.2
Takahata, T.3
Sasaki, M.4
Tateishi, T.5
-
30
-
-
0028970499
-
Population pharmacokinetics of docetaxel during phase i studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation
-
Launay-Iliadis MC, Bruno R, Cosson V, et al,. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47-54.
-
(1995)
Cancer Chemother Pharmacol
, vol.37
, pp. 47-54
-
-
Launay-Iliadis, M.C.1
Bruno, R.2
Cosson, V.3
-
31
-
-
57349120552
-
Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling
-
Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A,. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 2008; 36: 2405-2409.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 2405-2409
-
-
Barter, Z.E.1
Chowdry, J.E.2
Harlow, J.R.3
Snawder, J.E.4
Lipscomb, J.C.5
Rostami-Hodjegan, A.6
-
32
-
-
78751558968
-
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients
-
Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J,. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
-
(2011)
Clin Pharmacokinet
, vol.50
, pp. 99-110
-
-
Ulldemolins, M.1
Roberts, J.A.2
Rello, J.3
Paterson, D.L.4
Lipman, J.5
-
33
-
-
0029800979
-
Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein
-
Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP,. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996; 14: 147-151.
-
(1996)
Invest New Drugs
, vol.14
, pp. 147-151
-
-
Urien, S.1
Barre, J.2
Morin, C.3
Paccaly, A.4
Montay, G.5
Tillement, J.P.6
-
34
-
-
33746678595
-
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer
-
Lu JF, Eppler SM, Wolf J, et al,. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80: 136-145.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 136-145
-
-
Lu, J.F.1
Eppler, S.M.2
Wolf, J.3
-
35
-
-
79954571612
-
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding
-
Graham RA, Lum BL, Cheeti S, et al,. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2012; 17: 2512-2520.
-
(2012)
Clin Cancer Res
, vol.17
, pp. 2512-2520
-
-
Graham, R.A.1
Lum, B.L.2
Cheeti, S.3
-
36
-
-
0024310292
-
Clinical relevance of alpha 1 acid glycoprotein in health and disease
-
Routledge PA,. Clinical relevance of alpha 1 acid glycoprotein in health and disease. Prog Clin Biol Res 1989; 300: 185-198.
-
(1989)
Prog Clin Biol Res
, vol.300
, pp. 185-198
-
-
Routledge, P.A.1
-
37
-
-
0033929869
-
Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer
-
Duche JC, Urien S, Simon N, Malaurie E, Monnet I, Barre J,. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000; 33: 197-202.
-
(2000)
Clin Biochem
, vol.33
, pp. 197-202
-
-
Duche, J.C.1
Urien, S.2
Simon, N.3
Malaurie, E.4
Monnet, I.5
Barre, J.6
-
38
-
-
62949175363
-
Lack of effect of subject posture on intravenous midazolam clearance: Implications for hepatic cytochrome P450 3A phenotyping
-
Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr,. Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol 2009; 67: 374-375.
-
(2009)
Br J Clin Pharmacol
, vol.67
, pp. 374-375
-
-
Ma, J.D.1
Nafziger, A.N.2
Mylott, W.3
Haughey, D.B.4
Rocci, Jr.M.L.5
Bertino, Jr.J.S.6
-
39
-
-
19944427867
-
Factors affecting cytochrome P-450 3A activity in cancer patients
-
Baker SD, van Schaik RH, Rivory LP, et al,. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10: 8341-8350.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8341-8350
-
-
Baker, S.D.1
Van Schaik, R.H.2
Rivory, L.P.3
-
40
-
-
0141672041
-
The binding of HIV-1 protease inhibitors to human serum proteins
-
Schon A, del Mar Ingaramo M, Freire E,. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003; 105: 221-230.
-
(2003)
Biophys Chem
, vol.105
, pp. 221-230
-
-
Schon, A.1
Del Mar Ingaramo, M.2
Freire, E.3
-
41
-
-
0031908050
-
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
-
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S,. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-359.
-
(1998)
Br J Clin Pharmacol
, vol.45
, pp. 355-359
-
-
Kupferschmidt, H.H.1
Fattinger, K.E.2
Ha, H.R.3
Follath, F.4
Krahenbuhl, S.5
-
42
-
-
0022539064
-
Plasma drug binding: Implications for anesthesiologists
-
Wood M,. Plasma drug binding: implications for anesthesiologists. Anesth Analg 1986; 65: 786-804.
-
(1986)
Anesth Analg
, vol.65
, pp. 786-804
-
-
Wood, M.1
-
45
-
-
34548787904
-
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study
-
Launay-Vacher V, Oudard S, Janus N, et al,. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
-
(2007)
Cancer
, vol.110
, pp. 1376-1384
-
-
Launay-Vacher, V.1
Oudard, S.2
Janus, N.3
-
46
-
-
84859803615
-
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients
-
Takahashi N, Miura M, Niioka T, Sawada K,. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol 2012; 69: 999-1004.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 999-1004
-
-
Takahashi, N.1
Miura, M.2
Niioka, T.3
Sawada, K.4
-
47
-
-
0028307740
-
P-glycoprotein, multidrug resistance and tumor progression
-
Bradley G, Ling V,. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 223-233.
-
(1994)
Cancer Metastasis Rev
, vol.13
, pp. 223-233
-
-
Bradley, G.1
Ling, V.2
-
48
-
-
33746881712
-
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
-
Widmer N, Decosterd LA, Csajka C, et al,. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006; 62: 97-112.
-
(2006)
Br J Clin Pharmacol
, vol.62
, pp. 97-112
-
-
Widmer, N.1
Decosterd, L.A.2
Csajka, C.3
-
49
-
-
1942455391
-
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours
-
Blair EY, Rivory LP, Clarke SJ, McLachlan AJ,. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Br J Clin Pharmacol 2004; 57: 416-426.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 416-426
-
-
Blair, E.Y.1
Rivory, L.P.2
Clarke, S.J.3
McLachlan, A.J.4
-
50
-
-
18344394148
-
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
-
Mould DR, Holford NH, Schellens JH, et al,. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71: 334-348.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 334-348
-
-
Mould, D.R.1
Holford, N.H.2
Schellens, J.H.3
|